Cancer Research Funding

Current Funding Opportunities

MCW Cancer Center Pilot Funding Program

Grant support resources are now available from the MCW Cancer Center.

National Cancer Institute (NCI)

Open AllClose All
  Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed (Deadlines: 2/14/18; 7/10/18; and 10/8/18)

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Applications due February 14, 2018; July 10, 2018; October 8, 2018

  Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional) (Deadlines: 10/5/18; 6/5/19; 2/5/20; and 10/5/20)

Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

Applications due October 5, 2018; June 5, 2019; February 5, 2020; and October 5, 2020

National Institutes of Health (NIH)

Open AllClose All
  Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01/R21 Clinical Trial Optional) (Deadline: 6/5/18 (R01); 6/16/18 (R21))

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01/R21 Clinical Trial Optional)

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

Deadlines:

  • June 5, 2018 (R01)
  • June 16, 2018 (R21)
  The Role of Mobile Genetic Elements in Cancer (R01) (Deadline: 6/5/18 or 10/5/18)

The Role of Mobile Genetic Elements in Cancer (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

Deadline: June 5, 2018 OR October 5, 2018

  Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) (Deadline: 6/13/18 or 10/15/18)

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)

This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Deadline: June 13, 2018 OR October 15, 2018

  Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) (Deadline: 6/16/18)

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Deadline: June 16, 2018

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) (Deadline: 6/16/18 or 10/16/18)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Deadline: June 16, 2018 OR October 16, 2018

  Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21/R01 Clinical Trial Optional) (Deadline: 2/5/18; 2/16/18; 6/5/18; 6/16/18)

Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21 / R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models.

Deadlines

  • Due February 5, 2018
  • Due February 16, 2018
  • Due June 5, 2018
  • Due June 16, 2018
  Investigator-Initiated Genomic Medicine Research (R01/R21 Clinical Trial Optional) (Deadline: 6/20/18)

Investigator-Initiated Genomic Medicine Research (R01/R21 Clinical Trial Optional)

This opportunity supports research opportunities that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use

Deadline: June 20, 2018

  Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required) (Deadline: 2/14/18; 6/28/18; 10/11/18)

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Deadline:

  • February 14, 2018
  • June 28, 2018
  • October 11, 2018
  End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21/R01 Clinical Trial Optional) (Deadlines: 6/5/18; 6/16/18)

End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness  (R21 / R01 Clinical Trial Optional)

This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers

Deadlines:

  • Due June 5, 2018
  • Due June 16, 2018
  Community Partnerships to Advance Research (CPAR) (R01/R21 Clinical Trial Optional) (Deadline: 6/5/18; 6/16/18)

Community Partnerships to Advance Research (CPAR) (R01 / R21 Clinical Trial Optional)

This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

Deadlines:

  • June 5, 2018
  • June 16, 2018
  Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) (Deadline: 6/15/18)

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Application due June 15, 2018

  Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 - Clinical Trial Optional) (Deadline: 6/16/18)

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 - Clinical Trial Optional)

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. (Supported by NIA & NCI)

Deadline: June 16, 2018

  Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional) (Deadline: 6/16/18)

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. (Supported by NIA & NCI)

Deadline: June 16, 2018

  Metabolic Reprogramming to Improve Immunotherapy (R01) (Deadline: 6/5/18 or 10/5/18)

Metabolic Reprogramming to Improve Immunotherapy (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

Deadline: June 5, 2018 OR October 5, 2018

  Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) (Deadline: 6/19/18 or 11/19/18)

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Deadline: June 19, 2018; November 19, 2018

  Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) (Deadline: 6/19/18 or 11/19/18)

Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. 

Deadline: June 19, 2018; November 19, 2018

  Image-guided Drug Delivery (R01 Clinical Trial Optional) (Deadline: 6/21/18)

Image-guided Drug Delivery (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

Application due June 21, 2018

  Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21 Clinical Trial Optional) (Deadline: 6/27/18)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21 Clinical Trial Optional)

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Deadline: June 27, 2018

  Research Answers to National Cancer Institute's (NCI) Provocative Questions (Deadline: 6/29/18)

Research Answers to National Cancer Institute's (NCI) Provocative Questions

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Deadline: June 29, 2018

  Revision Applications to National Cancer Institute's (NCI) Supported U01/R01 Awards to Include Research on the NCI's Provocative Questions (U01/R01 Clinical Trial Optional) (Deadline: 6/29/18; LOI due 30 days prior)

Revision Applications to National Cancer Institute's (NCI) Supported U01/R01 Awards to Include Research on the NCI's Provocative Questions (U01/R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 or R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01/R01 award.

Deadline: June 29, 2018 (LOI due 30 days prior)

  Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed) (Deadline: 6/30/18)

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed)

This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents. The DRSN was also developed to assist in issues of cancer drug resistance in the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical industry partners) in NCI-sponsored early phase clinical trials.

This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.

Deadline: June 30, 2018

  Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp Clinical Trial Not Allowed) (Deadline: 7/1/18)

Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp Clinical Trial Not Allowed)

The purpose of the administrative supplement is to provide support for NIH-funded investigators to prepare and deposit individual-level data from cancer epidemiology studies into NIH/NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.

Deadline: Due July 1, 2018

  Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01/R21 Clinical Trial Not Allowed) (Deadline: 7/11/18)

Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01/R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. NIEHS may support projects with a focus on innovative technology and method development.

Components of Participating Organizations:

  • National Cancer Institute (NCI)
  • National Institute of Environmental Health Sciences (NIEHS)

Deadline: July 11, 2018

  NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) (Deadline: 7/19/18)

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

The purpose of this Funding This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Deadline: July 19, 2018

  Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed) (Deadline: 7/30/18)

Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed)

The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s).

Deadline: July 30, 2018

  SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) (Deadline: 8/15/18)

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage.

This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Deadline: August 15, 2018

  Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01/R21 Clinical Trial Not Allowed) (Deadline: 8/16/18)

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01/R21 Clinical Trial Not Allowed)

The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.

This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for exploratory/developmental projects using the NIH R21 mechanism. The companion FOA, RFA-CA-18-013, is a parallel announcement for well-developed research projects using the NIH R01 funding mechanism.

Deadline: August 16, 2018

  Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44/R41/R42 - Clinical Trial Optional) (Deadline: 9/5/18)

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44/R41/R42 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the FOA encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in the low-resource settings, including remote or underserved populations within or outside the US. The technologies may include, but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to treatment options available in the local health system.

Deadline: September 5, 2018

  Bioengineering Research Partnerships (U01 Clinical Trial Optional) (Deadline: 5/8/18; 9/13/18)

Bioengineering Research Partnerships (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

Deadline:

  • May 8, 2018
  • September 13, 2018
  Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required) (Deadline: 9/19/18)

Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations.

The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations.Specifically, the focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation and dissemination in low-income rural areas, so proposals should seek to develop, adapt, and/or implement, and test interventions.

Deadline: Due September 19, 2018

  Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (Deadlines: 2/28/18; 5/29/18; 9/28/18)

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications to incorporate a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program from currently funded grant (see options below). Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.

As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Application Due: February 28, 2018; May 29, 2018; and September 28, 2018

  Novel Genomic Technology Development (R01/R21 Clinical Trial Not Allowed) (Deadline: 10/2/18)

Novel Genomic Technology Development (R01/R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) seeks grant applications to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.

Deadline: October 2, 2018

  Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional) (Deadline: 10/5/18)

Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.

Deadline: Due October 5, 2018

  Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed) (Deadline: 10/5/18)

Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)

The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. 

Deadline: October 5, 2018

  Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional) (Deadline: 1/9/19)

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional)

This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.

The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities

Deadline: January 9, 2019

  Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials) (Deadline: 3/6/19)

Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials)

This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #).

Deadline:

  • March 6, 2019
  Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) (Due Dates Vary by Awarding IC)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award.

Deadline: Due dates vary by awarding IC

  NCI Transition Career Development Award to Promote Diversity (Deadline: Standard Dates Apply)

NCI Transition Career Development Award to Promote Diversity

The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

Deadline: Standard Dates Apply

  Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Deadline: Standard Dates Apply

  Cancer Research Education Grants Program - Curriculum or Methods Development (R25) (Deadline: Standard Dates Apply)

Cancer Research Education Grants Program - Curriculum or Methods Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

  Cancer Research Education Grants Program - Research Experiences (R25) (Deadline: Standard Dates Apply)

Cancer Research Education Grants Program - Courses for Skills Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

  Cancer Research Education Grants Program - Research Experiences (R25) (Deadline: Standard Dates Apply)

Cancer Research Education Grants Program - Research Experiences (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

  Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Deadline: Standard Dates Apply

  Education and Health: New Frontiers (Deadline: Standard Dates Apply)

Education and Health: New Frontiers

The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

Deadline: Standard Dates Apply

  End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (Deadline: Standard Dates Apply)

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Deadline: Standard Dates Apply

  Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Deadline: Standard Dates Apply

  Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Deadline: Standard Dates Apply

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (Deadline: Standard Dates Apply)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Deadline: Standard Dates Apply

  Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Deadline: Standard Dates Apply

  Mentored Clinical Scientist Research Career Development Award (Deadline: Standard Dates Apply)

Mentored Clinical Scientist Research Career Development Award

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Deadline: Standard Dates Apply

  Methodology and Measurement in the Behavioral and Social Sciences (Deadline: Standard Dates Apply)

Methodology and Measurement in the Behavioral and Social Sciences

The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.

The participating NIH Institutes and Centers (ICs) encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants are strongly encouraged to contact the Scientific/Research Contact (see Section VII, Agency Contacts) of the IC that most closely matches their research focus to determine IC interest in the proposed research topic.

Deadline: Standard Dates Apply

  NCI Mentored Research Scientist Development Award to Promote Diversity (K01) (Deadline: Standard Dates Apply)

NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.

The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.

Deadline: Standard Dates Apply

  NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional) (Deadline: Standard Dates Apply)

NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.  

Deadline: Standard Dates Apply

  Population Health Interventions: Integrating Individual and Group Level Evidence (Deadline: Standard Dates Apply)

Population Health Interventions: Integrating Individual and Group Level Evidence

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Deadline: Standard Dates Apply

  Research Supplements to Promote Diversity in Health-Related Research (Due Dates Vary by Awarding IC)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)

The National Institutes of Health (NIH) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

Deadline: Due dates vary by awarding IC

  Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32) (Deadline: Standard Dates Apply)

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Research training programs will incorporate didactic, research, and career development elements to prepare individuals for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training.

Deadline: Standard Dates Apply

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Deadline: Standard Dates Apply

  Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).

This FOA encourages applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits.

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.

Deadline: Standard Dates Apply

  The Health of Sexual and Gender Minority (SGM) Populations (Deadline: Standard Dates Apply)

The Health of Sexual and Gender Minority (SGM) Populations

The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.

Deadline: Standard Dates Apply

  The NCI Transition Career Development Award (Deadline: Standard Dates Apply)

The NCI Transition Career Development Award

This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Deadline: Standard Dates Apply

  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Josh Gottheil Memorial Bone Marrow Transplant Career Development Awards (Deadline: 6/15/18)

Josh Gottheil Memorial Bone Marrow Transplant Career Development Awards

This award is given annually to support non-advanced practice level registered nurses working in bone marrow transplantation by providing financial assistance to attend a continuing education program that will further the nurses' professional goals as they related to transplant nursing. This award cannot be used for tuition in an academic program or for specialty certification.

Deadline: June 15, 2018

  "Networking2Save"- CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations (Deadline: 6/18/18)

"Networking2Save"- CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations

The Centers for Disease Control and Prevention's (CDC's) Office on Smoking and Health and Division of Cancer Prevention and Control announce the availability of fiscal year (FY) 2018 funds for Notice of Funding Opportunity (NOFO) CDC-RFA-DP18-1808: "Networking2Save" - CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations. This NOFO will fund a consortium of national networks to implement population-specific, public health-oriented strategies that impact the prevalence of commercial tobacco use and tobacco related cancers. Strategies and activities will focus on network administration and management; training and technical assistance; engagement of the target populations in national, state, tribal, territorial interventions; and mass reach health communications.

There is also a focus on promoting access to tobacco cessation services, cancer prevention, and treatment and survivor resources for populations experiencing disparities. This NOFO is competitive and eligibility for applicants is unrestricted. This announcement is only for non-research domestic activities supported by CDC. If research is proposed, the application will not be considered.

Deadline: June 18, 2018

  Unique AML Predisposition Grant-RUNX1/Alex’s Lemonade Stand (Deadline: LOI Due: 7/2/18; Application Due: 10/1/18)

Unique AML Predisposition Grant-RUNX1/Alex’s Lemonade Stand

The purpose of the grant is to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. Projects should focus on leukemia caused by familial RUNX1 mutations rather than sporadic AML with somatic RUNX1 mutations.

The Program is viewed as a long-term endeavor of collaboration and data sharing. We are especially interested in innovative and cross-disciplinary approaches to developing effective therapies.

Deadline: LOI Due: July 2, 2018 Application Due: 10/1/2018

  DoD Prostate Cancer, Idea Development Award (Deadline: Pre-Application due 7/6/18; Application due 9/27/18)

DoD Prostate Cancer, Idea Development Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are:

Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Multidisciplinary projects are especially encouraged.

Impact: Applications are required to address and provide a solution to one or more of the PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.

Preliminary Data: Due to this award's emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data is included or not, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.

Deadlines:

  • Preapplication July 6, 2018
  • Application September 27, 2018
  Rare Disease Research Grant Program: Appendix Cancer and Pseudomyxoma Peritonei (Deadline: 7/16/18)

Rare Disease Research Grant Program: Appendix Cancer and Pseudomyxoma Peritonei

NORD, with funding by the patient organization, Appendix Cancer / Pseudomyxoma Peritonei Research Foundation ("ACPMP"), is accepting applications for scientific and/or clinical research studies related to pseudomyxoma peritonei (PMP).

Deadline: July 16, 2018

  DoD Prostate Cancer, Impact Award (Deadline: Pre-Application due 7/19/18; Application due 10/18/18)

DoD Prostate Cancer, Impact Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Impact Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues, and ultimately make major advances toward eliminating death from prostate cancer and enhancing the well-being of Service members, Veterans, and all men experiencing the impact of the disease.

Deadlines

  • Preapplication July 19, 2018
  • Application October 18, 2018
  DoD Ovarian Cancer, Ovarian Cancer Academy- Early-Career Investigator Award (Deadline: Pre-Application 7/25/18)

DoD Ovarian Cancer, Ovarian Cancer Academy- Early-Career Investigator Award

The OCRP Ovarian Cancer Academy Award mechanism, which was initially created in FY09, is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.

The Ovarian Cancer Academy is a virtual career development and research training platform that consists of Early-Career Investigators and their Designated Mentors from different institutions, and an Academy Dean and Assistant Dean. The OCRP Ovarian Cancer Academy Early-Career Investigator Award is not a traditional career development award; the Early-Career Investigator is expected to participate in monthly webinars and annual workshops, and to communicate and collaborate with other members of the Academy (Early-Career Investigators; other Mentors; Dean; Assistant Dean) as well as with the advocacy community. Since the inception of the Academy, the Academy's Early-Career Investigators have presented at and chaired sessions for ovarian cancer-specific symposia and served on symposia review committees. They have also served as peer reviewers for the Department of Defense (DoD) OCRP and other funding agencies.

Deadline: Pre-Application due July 25, 2018

  DoD Ovarian Cancer Clinical Development Award (Deadline: Pre-Application 7/25/18)

DoD Ovarian Cancer Clinical Development Award

The OCRP Clinical Development Award is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life. The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Proof of concept demonstrating the potential utility of the proposed product or a prototype/ preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required.

Deadline: Pre-Application due July 25, 2018

  DoD Ovarian Cancer, Omics Consortium Development Award (Deadline: Pre-Application 7/25/18)

DoD Ovarian Cancer, Omics Consortium Development Award

The FY18 OCRP Omics Consortium Development Award supports a multi-institutional research effort conducted by leading ovarian cancer researchers and consumer advocates that specifically focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer disease with an emphasis on early detection and screening. This effort will be executed through a two-stage approach using two separate award mechanisms: the first is the current funding opportunity, the FY18 Omics Consortium Development Award, which will enable the consortium to lay the groundwork for the research project, including a proof of concept preliminary research project; and the second is an FY20 Omics Consortium Award, which will support the execution of the full research project.

Research projects proposed under the Omics Consortium Development Award must use large datasets (genomics, proteomics, metabolomics, other `omics) to focus on origin of disease. The long-term goal of the Omics Consortium is to facilitate improvements in early detection and screening of ovarian cancer, although immediate benefits of the consortium will be in initial diagnosis and therapy. With this in mind, applicants are encouraged to include rare subsets and putative pre-malignant lesions, as well as linkage to relevant interventional clinical trials, to be included in the data gathered by the Omics Consortium Development Award.

Deadline: Pre-Application due July 25, 2018

  R. Robert & Sally Funderburg Research Award in Gastric Cancer (Deadline: 7/27/18)

R. Robert & Sally Funderburg Research Award in Gastric Cancer

The objective of this award is to support an established investigator in the field of gastric biology whose research will enhance the fundamental understanding of gastric cancer pathobiology to ultimately prevent or develop a cure for the disease. Applications that do not denote a gastric biology focus and are not responsive to this announcement will not be submitted for review.

Deadline: July 27, 2018

  AACR Scientific Achievement Awards - AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention (Deadline: 8/8/18)

AACR Scientific Achievement Awards - AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

The AACR and the American Cancer Society established this award in 1992 to honor outstanding research accomplishments in the fields of cancer epidemiology, biomarkers, and prevention

Deadline: August 8, 2018

  AACR Scientific Achievement Awards - AACR Princess Takamatsu Memorial Lectureship (Deadline: 8/8/18)

AACR Scientific Achievement Awards - AACR Princess Takamatsu Memorial Lectureship

The AACR Princess Takamatsu Memorial Lectureship was established and first presented in 2007 in honor of the late Princess Takamatsu of Japan. During her extraordinary life, Her Imperial Highness Princess Takamatsu expended tremendous efforts toward the public and humanitarian cause of the eradication of cancer. She is regarded as an honored and respected figure in Japan, the United States, and within the international cancer research community as a whole.

This lectureship will recognize an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations.

Deadline: August 8, 2018

  DoD Prostate Cancer, Early Investigator Research Award (Deadline: Pre-Application 8/16/18: Application 9/6/18)

DoD Prostate Cancer, Early Investigator Research Award

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. This opportunity allows for early career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as a prostate cancer researcher of the future.

Deadlines:

  • Preapplication August 16, 2018
  • Application September 6, 2018
  DoD Prostate Cancer, Physician Research Award (Deadline: Pre-Application due 8/16/18; Application due 9/6/18)

DoD Prostate Cancer, Physician Research Award

Applications to the Fiscal Year 2018 (FY18) Prostate Cancer Research Program (PCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358).

The mission of the FY18 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care. Therefore, applications are required to address one or more of the following FY18 PCRP Overarching Challenges:

  • Develop treatments that improve outcomes for men with lethal prostate cancer
  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations
  • Define the biology of lethal prostate cancer to reduce death
  • Improve the quality of life for survivors of prostate cancer

The Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research.

Deadlines:

  • Preapplication August 16, 2018
  • Application September 6, 2018
  Career Development Award (CDA) (Deadline: 9/21/18)

Career Development Award (CDA)

The CDA provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.

The Foundation has funding in 2018 for breast cancer but also encourages applications in all other areas.

Deadline: September 21, 2018

  DoD Lung Cancer (Deadline: 9/26/18)

DoD Lung Cancer

Applications to the Fiscal Year 2018 (FY18) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). The goal of the FY18 LCRP is to eradicate deaths and suffering from lung cancer to better the health and welfare of the military Service members, Veterans, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

Deadline: September 26, 2018

  Translational Research Program (TRP) (Deadline: 10/31/18)

Translational Research Program (TRP)

The Leukemia & Lymphoma Society, Inc. (LLS) is a national voluntary health agency dedicated to the conquest of hematologic malignancies and relevant premalignant conditions. LLS supports research, patient aid, community service programs, advocacy, and public and professional education. The formation of the Translational Research Program (TRP) was to foster collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.

Deadline: October 31, 2018

  Collaborative Research Development Grant (Deadline To Be Announced)

Collaborative Research Development Grant

This grant provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions.

Deadline: To be Announced

  Liz Tilberis Early Career Award (Deadline To Be Announced)

Liz Tilberis Early Career Award

The Liz Tilberis Early Career Award is for junior faculty with a strong commitment to an investigative career in ovarian cancer research.

Deadline: To be Announced

  Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline: Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline: Continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

  Women's Cancer Research Grants (Deadline: Continuous)

Women's Cancer Research Grants

The FWC continues to seek additional funding to support expanded research priorities. Of special importance is increased funding for cervical, uterine, primary peritoneal, vaginal and vulvar cancer research. Additionally, the Foundation is seeking funding for a series of new types of research opportunities:

  • Post-Doctoral Fellowship grants: These grants are intended to attract and support promising young scientists and clinician/scientists to ensure the next generation of skilled researchers dedicated to gynecologic cancer research.
  • Career Development Awards: These grants are similar to the NIH CDA, K series awards, and are awarded to applicants who wish to further develop their careers in gynecologic cancer biomedical, behavioral or clinical research
  • Paired grants: Junior investigators would join with senior investigators for grants lasting two to three years.
  • Innovative grants: These grants would provide funding for creative and imaginative research projects that show promise for significant breakthroughs, but have not been sufficiently advanced or developed to receive support through traditional funding channels.
  • Extension of the current, highly successful stimulus or “seed” grant program to include all gynecologic cancers, and the opportunity for competitive renewals at the conclusion of the one-year research grant.

Deadline continuous

Other Peer Review

Top